6 minute read
Proposed Slate of 2023–2025 AAN Board of Directors
Directors:
Wayne E. Anderson, DO, FAHS, FAAN
Jennifer Bickel, MD, FAAN*
Gregory J. Esper, MD, MBA, FAAN*
Larry B. Goldstein, MD, FAAN, FAHA
Lily Jung Henson, MD, MMM, FAAN
Shannon M. Kilgore, MD, FAAN
Jeffrey C. McClean II, MD, FAAN*
Bruce I. Ovbiagele, MD, MSc, MAS, MBA, MLS, FAAN
José H. Posas, MD, FAAN*
*New to the Board
The current President Elect, Carlayne E. Jackson, MD, FAAN, will begin her term as President on April 28, 2023. The current President, Orly Avitzur, MD, MBA, FAAN, will then serve on the Board of Directors as Immediate Past President. The following additional directors will serve as ex officio directors beginning on April 28:
Bruce H. Cohen, MD, FAAN, Chair, Advocacy Committee/ex officio
Brad C. Klein, MD, MBA, FAAN, Chair, Medical Economics and Practice Committee/ex officio
José G. Merino, MD, MPhil, FAHA, FAAN, Editor-in-Chief of
Neurology ®/ex officio
Maisha T. Robinson, MD, MSHPM, FAAN, Chair, Member Engagement Committee/ex officio
Mary E. Post, MBA, CAE, Chief Executive Officer/ex officio, non-voting
The Academy is comprised of two legal entities, the AAN and the AAN Institute. Most of the elected members of the AAN Board of Directors also serve ex officio on the Board of Directors of the AAN Institute, which includes an independent secretary-treasurer and additional members who serve in ex officio capacities. The AAN Institute Board of Directors will include the following additional members:
Brett M. Kissela, MD, MS, FAHA, FAAN, Secretary-Treasurer
Paul M. George, MD, PhD, FAAN, Chair, Science Committee/ex officio
Lyell K. Jones, Jr., MD, FAAN, Chair, Quality Committee/ex officio
José G. Merino, MD, MPhil, FAHA, FAAN, Editor-in-Chief of Neurology ®/ex officio
Joseph I. Sirven, MD, FAAN, Chair, Education Committee/ex officio
Mary E. Post, MBA, CAE, Chief continued from cover
Executive Officer/ex officio, non-voting
The slate of nominees will be presented to the voting membership for approval during the AAN’s 2023 Business Meeting on Saturday, April 22, from 4:00 p.m. to 4:30 p.m. ET during the Annual Meeting. The voting members present at the AAN Business Meeting also will be asked to vote on approving the following Bylaws amendments for the AAN. Voting members are Fellows (FAAN) and Neurologists, and Honorary and Senior members who had voting privileges in their most recent previous category of membership.
Adding the Chair of the Diversity, Equity, and Inclusion Committee to the AAN Board in Article IV, Section 1
Replacing all mentions of “Executive Director” with “CEO” throughout the Bylaws
Replacing “Chairman” with “Chair” in Article IV, Section 5
A complete copy of the proposed AAN Bylaws amendments is available at AAN.com/AmendedBylaws
For more information, contact Karen Kasmirski, Senior Governance Coordinator, at kkasmirski @ aan.com
Meet the AAN and AAN Institute Boards of Directors Nominees
Officers
President
Carlayne E. Jackson, MD, FAAN, is professor of neurology and otolaryngology at the University of Texas Health Science Center San Antonio (UTHSCSA), where she serves as chair of the Department of Neurology and holds the Edna Smith Dielmann Distinguished University Chair. She has served as president elect of the AAN since April 2021.
Jackson is a graduate of Texas A&M University, where she received a Bachelor of Science degree in chemical engineering. She obtained her medical degree at UTHSCSA, where she subsequently completed her neurology residency training and clinical neurophysiology fellowship. She has obtained board subspecialty certification in both clinical neurophysiology and neuromuscular medicine. She is a graduate of the Executive Leadership in Academic Medicine (ELAM) program sponsored by Drexel University College of Medicine.
Jackson serves as medical director for the South Texas ALSA Center of Excellence and the South Texas MDA Clinic. She is a member of the Western ALS Study Group, Northeast ALS Research Group, and the Muscle Study Group. She has participated in over 70 multicenter clinical trials in the areas of ALS, muscular dystrophy, and myasthenia gravis and has published over 260 abstracts, journal articles, and book chapters.
Jackson previously served as the chair of the AAN Meeting Management Committee and Board Planning Committee in addition to her role as secretary on the Executive Committee of the Board of Directors. She has also previously served the AAN as a member of the Science Committee, Meeting Management Committee, Leadership Development Committee, and the Board of Directors. She was a member of the Continuum® editorial board from 2007–2017. She co-chaired the ALS Measurement Development Panel and co-authored the ALS Practice Parameters. She has actively participated on the Education Subcommittee and the Neuromuscular Topic Work Group. Jackson participated in the Palatucci Advocacy Leadership Forum in 2013 and has been a delegate to Neurology on the Hill. She has served as a mentor in the Emerging Leaders Program, the Diversity Leaders Program, Women Leading in Neurology, and the Transforming Leaders Program and received the AAN Leading in Excellence Mentorship Award in 2017.
President Elect
Natalia S. Rost, MD, MPH, FAAN, FAHA, is chief of the stroke division at the Massachusetts General Hospital Department of Neurology and professor of neurology at Harvard Medical School. A cum laude graduate of Boston University School of Medicine, she also holds a Master of Public Health degree from Harvard School of Public Health. Rost trained in neurology and vascular neurology at Massachusetts General Hospital and Brigham and Women's Hospital residency and fellowship programs.
Rost is internationally recognized for her expertise in vascular neurology, neuroimaging of cerebrovascular disease, and big-data science applications to personalized clinical outcome prediction in acute stroke. A clinician-scientist at the helm of the ambitious research program dedicated to reducing global burden of stroke-related cognitive and functional disability, Rost is currently the MGH Research Scholar and Principal Investigator of DISCOVERY (www.discoverystudy.org), an innovative national clinical research network funded jointly by the National Institute of Neurological Disorders and Stroke/National Institute on Aging (U19NS115388) to address post-stroke cognitive impairment and dementia in diverse US populations.
Rost is the author of numerous peer-reviewed publications, book chapters, and co-author of the MGH Handbook of Neurology. She is the recipient of the 2012 Michael S. Pessin Stroke Leadership Award from the American Academy of Neurology, 2017 MGH Neurology Department’s Ray Adams Clinical Mentor Award, and 2021 Leading in Excellence Through Mentorship Award from the AAN Leadership Program. She is a Fellow of the American Academy of Neurology and American Heart Association, former president of the Boston Board of the American Heart Association (2014-2016), scientific chair of the 2022 NINDS Alzheimer’s Disease-Related Dementias Summit, and she serves as associate editor of the journal Stroke
Among her professional accomplishments, Rost is particularly proud of her career-long service to the American Academy of Neurology, where she currently serves as chair of the Science Committee and vice chair of the Committee on Public Engagement, including her key leadership role in the AAN’s Brain Health Initiative.
Vice President
Janis M. Miyasaki, MD, MEd, FRCPC, FAAN, is a graduate of the University of Toronto medical school, neurology residency program, and movement disorders fellowship. From 1994 to 1998, she was a community neurologist. In 1999, she became faculty at the University of Toronto, assuming the roles as director of education for neurology for four hospitals, ward chief, member of the board of trustees for the University Health Network; president of the Medical Staff Association; president of the Canadian Movement Disorders Group; deputy physician-in-chief, Toronto Western Hospital; and associate clinical director of the Movement Disorders Centre at Toronto Western Hospital from 2001 to 2013. In 2007, Miyasaki initiated the first neurologist-led palliative care for movement disorders in the world.
Since 2014, Miyasaki joined the University of Alberta and is currently division director neurology, Department of Medicine and Zone Section Head Neurology, Edmonton Zone; and co-director of the Neuropalliative and Advanced Symptom Management Clinic. She is an active clinical researcher, holding grants, mentoring young researchers in movement disorders, physician wellness, and equity (Scopus h-index 52). She is the first director of Equity, Diversity, and Inclusion for the Department of Medicine at the University of Alberta.
Her AAN activities began in 2000 through writing a guideline on Parkinson's disease. Since that time, she has worked on the Practice Committee, Technology and Therapeutics Subcommittee, Practice Improvement Subcommittee, Patient Safety Subcommittee, and Education Committee, Business Innovation Subcommittee, Physician Wellness and Burnout Work Group, Wellness Subcommittee, and numerous task forces. Miyasaki has been a member of the Board of Directors from 2011–2017, AAN treasurer from 2017–2021, and vice president of the AAN from 2021–2023.
Secretary
Sarah M. Benish, MD, FAAN, is currently the physician co-chief for M Health/ Fairview Neuroscience service line. She is an associate professor of neurology at the University of Minnesota and is also the division head for general neurology. She enjoys her clinic time as a general neurologist. Over her career, she has
